We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
+39.05%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$1.73B
AUM Growth
+$226M
Cap. Flow
-$19.1M
Cap. Flow %
-1.1%
Top 10 Hldgs %
61.35%
Holding
45
New
12
Increased
7
Reduced
6
Closed
9

Top Buys

Rank Stock Value
1
DMRA
Damora Therapeutics, Inc. Ordinary Shares
DMRA
+$49.8M
2
EYPT icon
EyePoint Inc
EYPT
+$42.2M
3
ERAS icon
Erasca
ERAS
+$37.5M
4
CRVS icon
Corvus Pharmaceuticals
CRVS
+$36M
5
NUVL
Nuvalent
NUVL
+$28.9M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$59.6M
2
ORKA
Oruka Therapeutics
ORKA
+$53.1M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$44.9M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$39.3M
5
ELVN icon
Enliven Therapeutics
ELVN
+$39.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.71%
2 Financials 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZURA icon
26
Zura Bio
ZURA
$497M
$19.3M 1.12%
+3,250,000
New +$19.6M
SABS icon
27
SAB Biotherapeutics
SABS
$268M
$16.9M 0.98%
4,401,500
– –
PALI icon
28
Palisade Bio
PALI
$339M
$12.6M 0.73%
7,181,062
-4,263,938
-37% -$7.75M
KPTI icon
29
Karyopharm Therapeutics
KPTI
$168M
$10.9M 0.63%
+1,950,000
New +$14.9M
IKT icon
30
Inhibikase Therapeutics
IKT
$366M
$9.07M 0.52%
5,397,488
– –
ANTX icon
31
AN2 Therapeutics
ANTX
$177M
$7.98M 0.46%
+2,333,713
New +$4.82M
PEPG icon
32
PepGen
PEPG
$133M
$7.92M 0.46%
4,475,000
+1,075,000
+32% +$6.04M
AVTX icon
33
Avalo Therapeutics
AVTX
$976M
$7.21M 0.42%
483,000
– –
HLXC
34
Helix Acquisition Corp III
HLXC
$5.08M 0.29%
+500,000
New +$5.12M
LONA
35
LeonaBio Inc
LONA
$69.4M
$4.77M 0.28%
464,398
– –
RLMD icon
36
Relmada Therapeutics
RLMD
$544M
$4.41M 0.26%
+633,901
New +$3M
CNTA
37
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-1,000,000
Closed -$25M
CTMX icon
38
CytomX Therapeutics
CTMX
$705M
– –
-7,692,300
Closed -$32.8M
DRUG
39
Bright Minds Biosciences
DRUG
$700M
– –
-18,851
Closed -$1.47M
PTGX icon
40
Protagonist Therapeutics
PTGX
$8.75B
– –
-450,000
Closed -$39.3M
RAPT
41
DELISTED
RAPT Therapeutics
RAPT
– –
-250,000
Closed -$8.47M
REPL icon
42
Replimune Group
REPL
$814M
– –
-1,425,000
Closed -$13.9M
TERN
43
DELISTED
Terns Pharmaceuticals
TERN
– –
-1,475,000
Closed -$59.6M
CTNM
44
Contineum Therapeutics
CTNM
$526M
– –
-816,326
Closed -$9.33M
ORKA
45
Oruka Therapeutics
ORKA
$5.56B
– –
-1,753,054
Closed -$53.1M
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Commodore Capital held 45 positions worth $1.73B, up 15% from $1.5B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Commodore Capital's Q1 2026 filing shows 12 new, 7 increased, 6 reduced and 9 closed positions. Its largest new stake was Damora Therapeutics, Inc. Ordinary Shares: 1,939,000 shares worth $50.2M. The largest sale was Terns Pharmaceuticals, an estimated $59.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

  • Commodore Capital's largest Q1 2026 buy was Damora Therapeutics, Inc. Ordinary Shares: 1,939,000 shares worth $50.2M.
  • Commodore Capital added most to Nuvalent in Q1 2026, an estimated $28.9M increase.
  • Commodore Capital's biggest Q1 2026 reduction was Xenon Pharmaceuticals, cutting an estimated $44.9M.
  • Commodore Capital fully exited Terns Pharmaceuticals in Q1 2026, selling an estimated $59.6M.
  • Commodore Capital's ten largest holdings make up 61% of its $1.73B portfolio in Q1 2026.
  • Commodore Capital opened 12 new positions and closed 9 in Q1 2026.
  • Commodore Capital's portfolio value rose 15% quarter-over-quarter to $1.73B.

Based on Commodore Capital's 13F filing for Q1 2026, filed 15 May 2026.